1Farooq, S, Taylor, M. Clozapine. Br J Psychiatry 2011; 198(4): 247–9.
2Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a metaanalysis. Lancet 2009; 373: 31–41.
3McEvoy, JP, Lieberman, JA, Stroup, TS, Davis, SM, Meltzer, HY, Rosenheck, RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600–10.
4Lewis, SW, Barnes, TRE, Davies, L, Murray, RM, Dunn, G, Hayhurst, KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32: 715–23.
5Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2006; 63: 622–9.
6Brunette, MF, Drake, RE, Xie, H, McHugo, GJ, Green, AI. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 2006; 32: 637.
7Tiihonen, J, Lönnqvist, J, Wahlbeck, K, Klaukka, T, Niskanen, L, Tanskanen, A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620–7.
8Warnez, S, Alessi-Severini, S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 2014; 14: 102.
9Downs, J, Zinkler, M. Clozapine: national review of postcode prescribing. Psychiatr Bull 2007; 31: 384–7.
10Howes, O, Vergunst, F, Gee, S, McGuire, P, Kapur, S, Taylor, D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012; 201(6): 481–5.
11Wheeler, AJ. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother 2008; 42(6): 852–60.
13Nielsen, J, Dahm, M, Lublin, H, Taylor, D. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2009; 24(7): 965–71.
14Moher, D, Liberati, A, Tetzlaff, J, Altman, DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151(4): 264–9.
16Taylor, DM, Young, C, Paton, C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003; 64: 30–4.
17Gee, S, Vergunst, F, Howes, O, Taylor, D. Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 2014; 130(1): 16–24.
18Kelly, DL, Ben-Yoav, H, Payne, GF, Winkler, TE, Chocron, SE, Kim, E, et al. Blood draw barriers for treatment with clozapine and development of point-of-care monitoring device. Clin Schizophr Relat Psychoses Spring 2018; 12(1): 23–30.
19Swinton, M, Ahmed, AG. Reasons for non-prescription of clozapine in treatment-resistant schizophrenia. Crim Behav Ment Health 1999; 9(3): 207–14.
20Najim, H, Heath, D, Singh, P. Antipsychotic prescribing before clozapine in a community psychiatric hospital: a case note review. Psychiatr Danub 2013; 25(Suppl 2): S165–70.
21Grover, S, Hazari, N, Chakrabarti, S, Avasthi, A. Delay in initiation of clozapine: a retrospective study from a tertiary care hospital in North India. Psychiatry Res 2015; 226(1): 181–5.
22Tungaraza, TE, Farooq, S. Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Ther Adv Psychopharmacol 2015; 5(2): 88–96.
23Apiquian, R, Fresán, A, De la Fuente-Sandoval, C, Ulloa, RE, Nicolini, H. Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns. BMC Psychiatry 2004; 4(1): 12.
24Cirulli, G. Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units. The Psychiatrist 2005; 29(10): 377–80.
25Stroup, TS, Gerhard, T, Crystal, S, Huang, C, Olfson, M. Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv 2014; 65(2): 186–92.
26Gören, JL, Rose, AJ, Engle, RL, Smith, EG, Christopher, ML, Rickles, NM, et al. Organizational characteristics of Veterans Affairs clinics with high and low utilization of clozapine. Psychiatr Serv 2016; 67(11): 1189–96.
27Kelly, DL, et al. Addressing barriers to clozapine underutilization: a national effort. Psychiatr Serv 2018; 69: 224–7.
28Carruthers, J, Radigan, M, Erlich, MD, Gu, G, Wang, R, Frimpong, EY, et al. An initiative to improve clozapine prescribing in New York State. Psychiatr Serv 2015; 67(4): 369–71.
29Bogers, JP, Bui, H, Herruer, M, Cohen, D. Capillary compared to venous blood sampling in clozapine treatment: patients׳ and healthcare practitioners׳ experiences with a point-of-care device. Eur Neuropsychopharmacol 2015; 25(3): 319–24.
30Nielsen, J, Thode, D, Stenager, E, Andersen, KØ, Sondrup, U, Hansen, TN, et al. Hematological clozapine monitoring with a point-of-care device: a randomized cross-over trial. Eur Neuropsychopharmacol 2012; 22(6): 401–5.
31Kennedy, JL, Altar, CA, Taylor, DL, Degtiar, I, Hornberger, JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 2014; 29(2): 63–76.